Ralaniten (EPI-002) is a potent and orally active antagonist of the androgen receptor-N-terminal domain (AR-NTD). Ralaniten inhibits AR transcriptional activity, with IC50 of 7.4 μM. Ralaniten can be used for the research of castration-resistant prostate cancer (CRPC).
IC50&Target
IC50: 7.4 μM (AR-NTD)
体外研究
EPI-002 (5-35 μM; 2-3 days) reduces AR-dependent proliferation of LNCaP cells, and has no effect on the viability of PC3 human prostate cancer cells that do not express functional AR.
Ralaniten (10-35 μM; 4 h) inhibits transactivation of the AR N-terminal domain (NTD) induced by forskolin in LNCaP cells.
体内研究
EPI-002 (100 mg/kg; p.o. twice daily for 28 days) inhibits the VCaP tumor growth in castrated mice.
Animal Model:
Male NOD-SCID mice bearing subcutaneous tumors were castrated
Dosage:
100 mg/kg
Administration:
P.o. twice daily for 28 days
Result:
Inhibited the growth of castration-resistant prostate cancer (CRPC) xenografts that express AR splice variants.
分子式
C21H27ClO5
分子量
394.89
CAS号
1203490-23-6
运输条件
Room temperature in continental US; may vary elsewhere.